2025-12-29 - Analysis Report
Here's a breakdown of RXRX (Recursion Pharmaceuticals Inc.) based on the provided data, followed by a comprehensive analysis.

**0) Overview**

*   **RXRX Return:** -31.19%
*   **S&P 500 (VOO) Return:** 45.19%

**1) Return Rate Comparison and Analysis**

*   **Company Overview:** Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to discover, develop, and commercialize novel therapeutics.
*   **Divergence:**  The stock has significantly underperformed the S&P 500, with a current divergence of -73.9. This indicates a substantial difference in returns compared to the broader market. The relative divergence of 0.3 suggests it's near the lower end of its historical fluctuation range.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD  | Alpha   | Beta  | Cap(B) |
|------------|--------|------|---------|-------|--------|
| 2021-2023  | 22.0%  | 81.0% | 26.0%   | -0.2  | 5.1    |
| 2022-2024  | 11.0%  | 81.0% | -10.0%  | 0.1   | 3.5    |
| 2023-2025  | 11.0%  | 80.0% | -56.0%  | 0.1   | 2.2    |

*   **CAGR:** Compounded Annual Growth Rate - The CAGR decreased from 22% in 2021-2023 to 11% in subsequent periods, indicating slowing growth.
*   **MDD:** Maximum Drawdown - Consistently high MDD around 80-81% suggests significant volatility and risk.
*   **Alpha:** The alpha values dramatically decreased, turning negative in the more recent periods. This indicates a significant underperformance relative to the market after accounting for risk (Beta). In the most recent period, RXRX has an alpha of -56%.
*   **Beta:** A beta around 0.1 suggests that the stock's price movement has a very low correlation with the S&P 500.
*   **Cap(B):** Market Capitalization (in Billions) - This has shrunk significantly from $5.1B to $2.2B, indicating a substantial loss of investor confidence and market value.

**2) Recent Stock Price Fluctuations**

*   **Current Close:** $4.25
*   **Last-Market Data:** Price: $4.25, Previous Close: $4.40, Change: -3.41%
*   **5-day SMA:** $4.33
*   **20-day SMA:** $4.50
*   **60-day SMA:** $4.99

The current price is below all three moving averages (5-day, 20-day, and 60-day SMA), suggesting a short-term and medium-term downtrend.

**3) Indicator Analysis**

*   **MRI (Market Risk Indicator):** 1.0 (High Investment Recommended) - This seems contradictory given the other data. Further investigation into how this MRI is calculated is needed.
*   **RSI (Relative Strength Index):** 38.50 - This is approaching oversold territory (below 30), potentially suggesting a possible short-term rebound.
*   **PPO (Percentage Price Oscillator):** -0.0178 - Negative PPO indicates that the shorter-term moving average is below the longer-term moving average, confirming a downtrend.
*   **Hybrid Signal:**  cash_0%_Buy 100% of cash (225 shares - Very Safe - MRI:0.90). It suggests investing a small amount regularly. The "Very Safe" assessment and high MRI are questionable.
*   **Recent Divergence Change:** -0.5 (Negative - Short-term decline)
*   **Price Fluctuation:** The recent change of -3.41% indicates a short-term fluctuation issue.
*   **Expected Return:** -552.1% - This is an extremely negative expected return, suggesting very high risk and potential for further decline compared to S&P 500.

**4) Recent News & Significant Events**

*   **Cathie Wood Doubling Down:** ARK Invest's buying could signal confidence, but the questions in the headlines ("Should you buy?") indicate uncertainty.
*   **Analyst Focus on REC-4881 Data & CEO Transition:** Focus on key data is important for the long term of the company. CEO transition data may increase stock price volatility.
*   **Jim Cramer's Comments:** Describing the stock as "speculative" highlights the high-risk nature of the investment.
*   **Exscientia Merger & Clinical Data Readout:** Opinions regarding Exscientia and clinical data are important in determining the success of the company.
*   **J.P. Morgan Upgrade:** This is a positive signal, but needs to be weighed against other negative indicators.
*   **Cathie Wood Doubling Down (Again):** This reinforces the ARK Invest signal.

**4-2) Analyst Opinions**

*   **Consensus:** Hold (2.50)
*   **Target Price:** The average target price of $7.00 is significantly higher than the current price of $4.25, suggesting potential upside. However, the wide range ($3.00 - $11.00) reflects uncertainty.
*   **Recent Rating Changes:** (No Data) Lack of recent upgrades or downgrades makes analysis difficult.

**5) Recent Earnings Analysis**

| 날짜       | EPS     | 매출      |
|------------|---------|-----------|
| 2025-11-05 | -0.36   | 0.01 B$   |
| 2025-08-05 | -0.41   | 0.02 B$   |
| 2025-05-05 | -0.50   | 0.01 B$   |
| 2024-11-06 | -0.34   | 0.03 B$   |
| 2025-11-05 | -0.34   | 0.03 B$   |

*   **EPS (Earnings Per Share):**  Consistently negative EPS values indicate a lack of profitability. EPS appears to be trending positively.
*   **Revenue:** Revenue is low and has fluctuated, but appears to be trending downwards.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-09-30 | $0.00B  | -194.74%      |
| 2025-06-30 | $0.02B  | -5.54%        |
| 2025-03-31 | $0.01B  | -47.31%       |
| 2024-12-31 | $0.00B  | -183.62%      |
| 2024-09-30 | $0.03B  | 53.69%        |

**Capital and Profitability:**

| Quarter    | Equity  | ROE      |
|------------|---------|----------|
| 2025-09-30 | $1.05B  | -15.50%  |
| 2025-06-30 | $0.92B  | -18.70%  |
| 2025-03-31 | $0.93B  | -21.68%  |
| 2024-12-31 | $1.03B  | -17.29%  |
| 2024-09-30 | $0.52B  | -18.27%  |

*   **Revenue:** Revenue is very low and inconsistent.
*   **Profit Margin:**  Large negative profit margins indicate significant losses.
*   **Equity:** While equity is high, the trend appears to be downward.
*   **ROE (Return on Equity):** Negative ROE values indicate the company is not generating profits from shareholder investments.

**7) Comprehensive Analysis**

RXRX (Recursion Pharmaceuticals Inc.) presents a high-risk investment profile. While it operates in the promising field of AI-driven drug discovery and has attracted attention from notable investors like Cathie Wood, several factors warrant caution:

*   **Underperformance:** The stock has significantly underperformed the S&P 500.
*   **High Volatility:**  The high MDD indicates a high degree of price volatility.
*   **Negative Profitability:**  Consistently negative EPS, profit margins, and ROE demonstrate a lack of profitability.
*   **Downtrend:** The stock is trading below its key moving averages, suggesting a continued downtrend.
*   **MRI Discrepancy:** The high MRI score seems inconsistent with the other negative indicators and warrants further scrutiny.
*   **Low Revenue:** Revenue is low and unstable.
*   **Analyst Uncertainty:** Despite a "Hold" consensus and a higher target price, the wide target price range reflects uncertainty.

**In summary, while RXRX may have long-term potential, it currently carries significant risk. The negative financial performance, high volatility, and underperformance relative to the market suggest caution. The positive signals, such as Cathie Wood's investment and the JP Morgan upgrade, need to be weighed carefully against the negative trends. A thorough understanding of the company's technology, pipeline, and market potential is crucial before considering an investment.**


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.